German Antitrust Authority Clears Path for BioNTech’s Strategic Acquisition

In a decisive move for Germany’s biotechnology sector, the Federal Cartel Office has granted unconditional approval for BioNTech’s proposed acquisition of competitor CureVac. The regulatory clearance, announced Tuesday, removes the final obstacle for BioNTech to proceed with obtaining up to 100 percent of CureVac’s shares, marking a significant consolidation within the mRNA technology landscape.

Germany’s competition watchdog conducted a thorough review of the proposed merger between the two mRNA specialists and identified no grounds for objection. The authority determined that the combination would not create monopolistic concerns within the mRNA technology sector, citing intense international competition from major pharmaceutical corporations as a balancing factor.

Andreas Mundt, President of the Cartel Office, explained that the divergent... Read more...